Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Up 0.5% – Should You Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares traded up 0.5% on Friday . The stock traded as high as $19.50 and last traded at $19.50. 300 shares were traded during trading, a decline of 34% from the average session volume of 453 shares. The stock had previously closed at $19.40.

Hikma Pharmaceuticals Price Performance

The company’s 50-day moving average is $17.80 and its two-hundred day moving average is $19.87. The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.